Mostrando 181 - 200 Resultados de 501 Para Buscar '"Odyssey"', tiempo de consulta: 0.15s Limitar resultados
  1. 181
  2. 182
  3. 183
  4. 184
  5. 185
  6. 186
  7. 187
  8. 188
  9. 189
  10. 190
    por Stroes, Erik, Guyton, John R., Lepor, Norman, Civeira, Fernando, Gaudet, Daniel, Watts, Gerald F., Baccara‐Dinet, Marie T., Lecorps, Guillaume, Manvelian, Garen, Farnier, Michel, Kostner, K., Lehman, S., Descamps, O., Gheyle, L., Mathieu, C., Bergeron, J., Elliott, T., Girard, G., Gupta, A., Hoag, G., Hove, J., Jeppesen, J., Kjærulf, J.H., Klarlund, K., Thomsen, K.K., Basart, D.C.G., Kooy, A., Liem, A., Swart, H., Troquay, R., Van Het Hof‐Wiersma, J, Viergever, P., Visseren, F., Doughty, R.N., Scott, R., Calvo, C., Díaz‐Díaz, J.L., Fuentes, F., Gil‐Extremera, B., Jericó, C., Matas Pericas, L., Mediavilla Garcia, J.D., Bolster, D.E., Koren, M., El Shahawy, M., Vardi, G., Weinstein, D., Zuzarte, K., Ginsberg, Henry, Robinson, Jennifer G., Rader, Daniel J., Cannon, Christopher P., Colhoun, Helen, Kastelein, John J.P., Huo, Yong, Olsson, Anders, Waters, David, Larrey, Dominique, Rosenson, Robert S., Patriarca, Peter A., Molenberghs, Geert, Tricoci, Pierluigi, Mahaffey, Kenneth W., Lopes, Renato D., Shah, Bimal R., Mehta, Rajendra H., Roe, Matthew T., Eapen, Zubin, Armaganijan, Luciana, Bertolami, Adriana, Leonardi, Sergio, Kolls, Bradley J., Jordan, J. Dedrick, Ducrocq, Grégory, Puymirat, Etienne, Mathews, Robin
    Publicado 2016
    “…Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin‐associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 191
  12. 192
  13. 193
  14. 194
  15. 195
  16. 196
  17. 197
  18. 198
    “…Thus, we aimed to compare the differences in physicians’ therapeutic decisions on alirocumab dose selection, and factors affecting these in CEE countries vs. other countries included in the ODYSSEY APPRISE study. METHODS: ODYSSEY APPRISE was a prospective, single-arm, phase 3b open-label (≥12 weeks to ≤30 months) study with alirocumab. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 199
  20. 200
Herramientas de búsqueda: RSS